Special Issue "Anti-Obesity Drugs"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 January 2013)

Special Issue Editor

Guest Editor
Dr. Raj Padwal
Faculty of Medicine & Dentistry, 2J2.00 WC Mackenzie Health Sciences Centre, University of Alberta, 8440 112 Street NW, Edmonton, AB T6G 2B7, USA
E-Mail: rpadwal@ualberta.ca
Interests: antiobesity drugs; bariatric surgery; bariatric care; hypertension; health outcomes research

Special Issue Information

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 800 CHF (Swiss Francs).

Keywords

  • antiobesity drug
  • sibutramine
  • orlistat
  • lipase inhibitor
  • cetilistat
  • contrave
  • empatic
  • buproprion
  • zonisamide
  • naltrexone
  • tesofensine
  • endocannabinoid receptor blocker
  • rimonabant
  • incretin
  • beta-3 blocker
  • adrenergic reuptake inhibitor
  • lorcaserin
  • serotonin agonist

Published Papers (3 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-3
p. 3494-3521
by  and
Pharmaceuticals 2010, 3(12), 3494-3521; doi:10.3390/ph3123494
Received: 5 October 2010; in revised form: 17 November 2010 / Accepted: 23 November 2010 / Published: 24 November 2010
Show/Hide Abstract | Cited by 5 | PDF Full-text (294 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Anti-Obesity Drugs)
p. 2398-2415
by , , , , ,  and
Pharmaceuticals 2010, 3(8), 2398-2415; doi:10.3390/ph3082398
Received: 8 June 2010; in revised form: 9 July 2010 / Accepted: 15 July 2010 / Published: 27 July 2010
Show/Hide Abstract | Cited by 2 | PDF Full-text (188 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Anti-Obesity Drugs)
p. 125-145
by  and
Pharmaceuticals 2010, 3(1), 125-145; doi:10.3390/ph3010125
Received: 8 November 2009; in revised form: 7 January 2010 / Accepted: 11 January 2010 / Published: 12 January 2010
Show/Hide Abstract | Cited by 2 | PDF Full-text (261 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Anti-Obesity Drugs)
Select/unselect all
Displaying article 1-3
Select articles Export citation of selected articles as:

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Manuscript ID: Pharmaceuticals-antiobsi-20090905-Tzotzas-gr
Type of Paper: Review
Title: The Effect of Incretin-Based Pharmacotherapy on Body Weight
Author: Spiridon Karras, Gerasimos Krassas and Themistoklis Tzotzas; E-Mail: tzotzas@otenet.gr
Abstract: Incretin–based pharmacotherapy, represented by Glucagon-Like Peptide-1(GLP-1) mimetics and DPP-4 inhibitors, offers a new therapeutic approach in Type 2 Diabetes Mellitus (T2DM).These glucosemodulatory agents enhance insulin secretion, lower fasting and postprandial glucose, suppress glucagon secretion and may have pleiotropic metabolic effects; additionally, they participate in the reduction of gastric emptying. Clinical studies demonstrated that GLP-1 mimetics increase postprandial satiety leading to reduced food intake and weight loss. These drugs induce food intake suppression mediated by distinct, but overlapping, peripheral and central pathways. On the contrary, DPP-4 inhibitors have a weight neutral effect. This review summarizes the current knowledge on the effect of incretin–based pharmacotherapy on body weight in T2DM and proposes an integrated model of the incretins on food intake .

Last update: 13 August 2012

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert